Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2025.0
(0.75%)
JPY 2025.0
(0.75%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.99 Billion JPY | 343.52% |
| 2022 | 1.35 Billion JPY | 244.65% |
| 2021 | -934 Million JPY | -4529.48% |
| 2020 | 21.08 Million JPY | -92.49% |
| 2019 | 280.89 Million JPY | -92.19% |
| 2018 | 3.59 Billion JPY | -43.37% |
| 2017 | 6.35 Billion JPY | -20.91% |
| 2016 | 8.03 Billion JPY | -26.36% |
| 2015 | 10.9 Billion JPY | 7.56% |
| 2014 | 10.14 Billion JPY | -8.28% |
| 2013 | 11.05 Billion JPY | 8.97% |
| 2012 | 10.14 Billion JPY | -0.13% |
| 2011 | 10.15 Billion JPY | -1.27% |
| 2010 | 10.28 Billion JPY | 3.79% |
| 2009 | 9.91 Billion JPY | -19.84% |
| 2008 | 12.36 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.45 Billion JPY | 24.33% |
| 2023 Q2 | 3.26 Billion JPY | 676.9% |
| 2023 FY | 5.99 Billion JPY | 343.52% |
| 2023 Q3 | 3.51 Billion JPY | 7.85% |
| 2023 Q4 | 5.99 Billion JPY | 70.28% |
| 2023 Q1 | 420 Million JPY | -68.91% |
| 2022 Q1 | 704 Million JPY | 175.37% |
| 2022 FY | 1.35 Billion JPY | 244.65% |
| 2022 Q4 | 1.35 Billion JPY | -12.56% |
| 2022 Q3 | 1.54 Billion JPY | 676.49% |
| 2022 Q2 | -268 Million JPY | -138.07% |
| 2021 FY | -934 Million JPY | -4529.48% |
| 2021 Q1 | -263.6 Million JPY | -1350.16% |
| 2021 Q2 | -1.19 Billion JPY | -353.0% |
| 2021 Q3 | -463 Million JPY | 61.23% |
| 2021 Q4 | -934 Million JPY | -101.73% |
| 2020 Q2 | -924.81 Million JPY | -590.4% |
| 2020 Q3 | 781.3 Million JPY | 184.48% |
| 2020 Q4 | 21.08 Million JPY | -97.3% |
| 2020 Q1 | 188.58 Million JPY | -32.86% |
| 2020 FY | 21.08 Million JPY | -92.49% |
| 2019 Q3 | 797.81 Million JPY | -39.33% |
| 2019 FY | 280.89 Million JPY | -92.19% |
| 2019 Q4 | 280.89 Million JPY | -64.79% |
| 2019 Q1 | 2.25 Billion JPY | -37.22% |
| 2019 Q2 | 1.31 Billion JPY | -41.78% |
| 2018 FY | 3.59 Billion JPY | -43.37% |
| 2018 Q3 | 5.28 Billion JPY | -6.48% |
| 2018 Q2 | 5.64 Billion JPY | -27.97% |
| 2018 Q1 | 7.84 Billion JPY | 23.43% |
| 2018 Q4 | 3.59 Billion JPY | -31.88% |
| 2017 Q2 | 7.49 Billion JPY | -12.12% |
| 2017 FY | 6.35 Billion JPY | -20.91% |
| 2017 Q4 | 6.35 Billion JPY | -13.8% |
| 2017 Q3 | 7.36 Billion JPY | -1.65% |
| 2017 Q1 | 8.52 Billion JPY | 6.16% |
| 2016 Q4 | 8.03 Billion JPY | -4.34% |
| 2016 FY | 8.03 Billion JPY | -26.36% |
| 2016 Q1 | 8.55 Billion JPY | -21.52% |
| 2016 Q3 | 8.39 Billion JPY | 4.65% |
| 2016 Q2 | 8.02 Billion JPY | -6.26% |
| 2015 Q4 | 10.9 Billion JPY | 27.9% |
| 2015 Q3 | 8.52 Billion JPY | 22.25% |
| 2015 Q2 | 6.97 Billion JPY | -14.75% |
| 2015 FY | 10.9 Billion JPY | 7.56% |
| 2015 Q1 | 8.18 Billion JPY | -19.31% |
| 2014 Q1 | 6.33 Billion JPY | -42.69% |
| 2014 Q3 | 6.39 Billion JPY | 7.76% |
| 2014 Q4 | 10.14 Billion JPY | 58.57% |
| 2014 FY | 10.14 Billion JPY | -8.28% |
| 2014 Q2 | 5.93 Billion JPY | -6.34% |
| 2013 Q1 | 7.81 Billion JPY | -22.98% |
| 2013 Q3 | 8.09 Billion JPY | 3.51% |
| 2013 Q4 | 11.05 Billion JPY | 36.58% |
| 2013 FY | 11.05 Billion JPY | 8.97% |
| 2013 Q2 | 7.81 Billion JPY | 0.07% |
| 2012 Q1 | 9.75 Billion JPY | -3.94% |
| 2012 FY | 10.14 Billion JPY | -0.13% |
| 2012 Q3 | 8.69 Billion JPY | -7.84% |
| 2012 Q2 | 9.42 Billion JPY | -3.39% |
| 2012 Q4 | 10.14 Billion JPY | 16.76% |
| 2011 Q1 | 8.83 Billion JPY | -14.14% |
| 2011 Q2 | 8.65 Billion JPY | -2.0% |
| 2011 FY | 10.15 Billion JPY | -1.27% |
| 2011 Q3 | 9.87 Billion JPY | 14.0% |
| 2011 Q4 | 10.15 Billion JPY | 2.93% |
| 2010 Q2 | 8.19 Billion JPY | 4.25% |
| 2010 Q4 | 10.28 Billion JPY | 16.86% |
| 2010 Q3 | 8.8 Billion JPY | 7.5% |
| 2010 FY | 10.28 Billion JPY | 3.79% |
| 2010 Q1 | 7.85 Billion JPY | 0.0% |
| 2009 FY | 9.91 Billion JPY | -19.84% |
| 2008 FY | 12.36 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | -389.143% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 99.863% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 98.463% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 101.729% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | 268.12% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 114.214% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 109.747% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 106.119% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | 998.351% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 111.563% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 118.201% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 21.179% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 22.992% |
| Tsumura & Co. | 1.61 Billion JPY | -271.022% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 113.569% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 117.4% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 96.531% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 77.494% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 79.325% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 15.127% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | -751.136% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | 191.944% |
| MedRx Co., Ltd | -1.72 Billion JPY | 448.372% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 168.743% |
| Solasia Pharma K.K. | -668 Million JPY | 997.006% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | 507.359% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 182.614% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 89.399% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | 302.38% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 106.088% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 153.838% |